US2022105156A1PendingUtilityA1

Methods of treatment for kidney disease

62
Assignee: UNIV WAKE FOREST HEALTH SCIENCESPriority: Mar 30, 2017Filed: Dec 14, 2021Published: Apr 7, 2022
Est. expiryMar 30, 2037(~10.7 yrs left)· nominal 20-yr term from priority
Inventors:James Williams
A61K 9/0019A61K 38/1866A61K 31/7105A61K 45/06A61K 38/195A61K 48/00A61P 13/12A61K 47/42
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides compositions and methods for treatment of a kidney disease with chemokine protein stromal cell-derived factor 1 (SDF-1), such as methods of treating a subject afflicted with or at risk of developing a kidney disease, comprising administering SDF-1 to a kidney of the subject in a treatment-effective amount.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a subject afflicted with or at risk of developing a kidney disease, comprising injecting a nucleic acid vector encoding stromal cell-derived factor 1 (SDF-1) to a kidney of the subject in a treatment-effective amount, which vector expresses said encoded SDF-1. 
     
     
         2 . The method of  claim 1 , wherein said vector is a plasmid vector or a viral vector. 
     
     
         3 . The method of  claim 1 , wherein said kidney disease is acute renal failure, chronic kidney disease, end-stage renal disease, or anemia. 
     
     
         4 . The method of  claim 1 , wherein said subject is a human subject. 
     
     
         5 . The method of  claim 1 , wherein said subject is a non-human mammalian subject. 
     
     
         6 . The method of  claim 1 , wherein said subject is a cat, a dog, or a horse. 
     
     
         7 . The method of  claim 1 , wherein said subject is a domestic cat. 
     
     
         8 . The method of  claim 1 , wherein said kidney disease is chronic interstitial nephritis. 
     
     
         9 . The method of  claim 1 , wherein said vector is provided in a pharmaceutically acceptable carrier. 
     
     
         10 . The method of  claim 9 , wherein said pharmaceutically acceptable carrier is sterile. 
     
     
         11 . The method of  claim 1 , wherein said injection is carried out at a plurality of sites on and/or within the kidney. 
     
     
         12 . The method of  claim 1 , wherein expression of said encoded SDF-1 results in decreased cellular disruption and/or decreased fibrosis of the kidney. 
     
     
         13 . The method of  claim 1 , wherein said SDF-1 is mammalian SDF-1. 
     
     
         14 . The method of  claim 1 , wherein said SDF-1 is human SDF-1α or human SDF-1β. 
     
     
         15 . The method of  claim 1 , wherein said SDF-1 is cat SDF-1 or dog SDF-1. 
     
     
         16 . The method of  claim 1 , wherein said SDF-1 is SDF-1α. 
     
     
         17 . A sterile injectable composition for the treatment of a kidney disease, comprising: SDF-1, and an aqueous carrier. 
     
     
         18 . The sterile injectable composition of  claim 17 , wherein said composition comprises collagen or gelatin. 
     
     
         19 . The sterile injectable composition of  claim 17 , wherein said composition further comprises VEGF. 
     
     
         20 . The sterile injectable composition of  claim 17 , wherein said SDF-1 is SDF-1α.

Join the waitlist — get patent alerts

Track US2022105156A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.